Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19

키워드

참고문헌 (190)

1. Amanat F, "SARS-CoV-2 vaccines : status report", Immunity, 52, pp.583~589 (2020)
2. Drosten C, "Identification of a novel coronavirus in patients with severe acute respiratory syndrome", N Engl J Med, 348, pp.1967~1976 (2003)
3. Zaki AM, "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia", N Engl J Med, 367, pp.1814~1820 (2012)
4. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
5. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2", Nat Microbiol, 5, pp.536~544 (2020)
6. Masters PS, "The molecular biology of coronaviruses", Adv Virus Res, 66, pp.193~292 (2006)
7. Cui J, "Origin and evolution of pathogenic coronaviruses", Nat Rev Microbiol, 17, pp.181~192 (2019)
8. Hofer U, "Viral evolution : fooling the coronavirus proofreading machinery", Nat Rev Microbiol, 11, pp.662~663 (2013)
9. DeDiego ML, "Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis", PLoS Pathog, 7, pp.e1002315~ (2011)
10. "Summary of probable SARS cases with onset of illness from 1 November 2002 to 1 July 2003"[URL]
11. Peiris JS, "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study", Lancet, 361, pp.1767~1772 (2003)
12. Wong CK, "Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome", Clin Exp Immunol, 136, pp.95~103 (2004)
13. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
14. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
15. Law HK, "Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells", Blood, 106, pp.2366~2374 (2005)
16. Nicholls JM, "Lung pathology of fatal severe acute respiratory syndrome", Lancet, 361, pp.1773~1778 (2003)
17. "MERS situation update, January 2020"[URL]
18. Ki M, "2015 MERS outbreak in Korea : hospital-to-hospital transmission", Epidemiol Health, 37, pp.e2015033~ (2015)
19. Arabi YM, "Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection", Ann Intern Med, 160, pp.389~397 (2014)
20. Zhou J, "Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus", Sci Adv, 3, pp.eaao4966~ (2017)
21. Zumla A, "Middle East respiratory syndrome", Lancet, 386, pp.995~1007 (2015)
22. Ng DL, "Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the united Arab Emirates, April 2014", Am J Pathol, 186, pp.652~658 (2016)
23. Alagaili AN, "Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia", MBio, 5, pp.e00884~ (2014)
24. De Benedictis P, "Alpha and lineage C betaCoV infections in Italian bats", Virus Genes, 48, pp.366~371 (2014)
25. Wacharapluesadee S, "Group C betacoronavirus in bat guano fertilizer, Thailand", Emerg Infect Dis, 19, pp.1349~1351 (2013)
26. Chowell G, "Transmission characteristics of MERS and SARS in the healthcare setting : a comparative study", BMC Med, 13, pp.210~ (2015)
27. Raj VS, "Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC", Nature, 495, pp.251~254 (2013)
28. Meyerholz DK, "Dipeptidyl peptidase 4 distribution in the human respiratory tract : implications for the Middle East respiratory syndrome", Am J Pathol, 186, pp.78~86 (2016)
29. Lau SK, "Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus : implications for pathogenesis and treatment", J Gen Virol, 94, pp.2679~2690 (2013)
30. Tynell J, "Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells", J Gen Virol, 97, pp.344~355 (2016)
31. Zhou J, "Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages : implications for pathogenesis", J Infect Dis, 209, pp.1331~1342 (2014)
32. Min CK, "Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity", Sci Rep, 6, pp.25359~ (2016)
33. Wu JT, "Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China : a modelling study", Lancet, 395, pp.689~697 (2020)
34. "coronavirus disease (covid-19) pandemic"[URL]
35. Xu X, "Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission", Sci China Life Sci, 63, pp.457~460 (2020)
36. Ji W, "Cross-species transmission of the newly identified coronavirus 2019-nCoV", J Med Virol, 92, pp.433~440 (2020)
37. Tommy Tsan-Yuk Lam, "Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins", Nature, 583(7815), pp.282~285 (2020), Springer Science and Business Media LLC[DOI]
38. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292 (2020)
39. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
40. Letko M, "Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses", Nat Microbiol, 5, pp.562~569 (2020)
41. Leung JM, "ACE-2 expression in the small airway epithelia of smokers and COPD patients : implications for COVID-19", Eur Respir J, 55, pp.2000688~ (2020)
42. Chen L, "The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2", Cardiovasc Res, 116, pp.1097~1100 (2020)
43. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
44. Lin L, "Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection", Gut, 69, pp.997~1001 (2020)
45. Spinato G, "Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection", JAMA, 323, pp.2089~ (2020)
46. Blanco-Melo D, "Imbalanced host response to SARS-CoV-2 drives development of COVID-19", Cell, 181, pp.1036~1045 (2020)
47. Vanderheiden A, "Type I and type III IFN restrict SARS-CoV-2 infection of human airway epithelial cultures", bioRxiv 2020. doi: 10.1101, 2020 (2020)
48. Konno Y, "SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant", bioRxiv 2020. doi: 10.1101, 2020 (2020)
49. Liao M, "Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19", Nat Med, 26, pp.842~844 (2020)
50. Qin C, "Dysregulation of immune response in patients with COVID-19 in Wuhan, China", Clin Infect Dis (2020)[DOI]
51. Xiaonan Zhang, "Viral and host factors related to the clinical outcome of COVID-19", Nature, 583(7816), pp.437~440 (2020), Springer Science and Business Media LLC[DOI]
52. Diao B, "Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019(COVID-19)", Front Immunol, 11, pp.827~ (2020)
53. Li T, "Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome", J Infect Dis, 189, pp.648~651 (2004)
54. Chu H, "Middle East respiratory syndrome coronavirus efficiently infects human primary t lymphocytes and activates the extrinsic and intrinsic apoptosis pathways", J Infect Dis, 213, pp.904~914 (2016)
55. Zheng M, "Functional exhaustion of antiviral lymphocytes in COVID-19 patients", Cell Mol Immunol, 17, pp.533~535 (2020)
56. Wang LF, "Review of bats and SARS", Emerg Infect Dis, 12, pp.1834~1840 (2006)
57. Glass WG, "Mechanisms of host defense following severe acute respiratory syndrome-coronavirus(SARS-CoV)pulmonary infection of mice", J Immunol, 173, pp.4030~4039 (2004)
58. Hogan RJ, "Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1", J Virol, 78, pp.11416~11421 (2004)
59. Frieman M, "Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease", J Virol, 86, pp.884~897 (2012)
60. Roberts A, "Aged BALB", c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans, 2005, pp.79, 5833~5838
61. Zhao J, "Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice", J Clin Invest, 121, pp.4921~4930 (2011)
62. Yang XH, "Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection", Comp Med, 57, pp.450~459 (2007)
63. McCray PB Jr, "Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus", J Virol, 81, pp.813~821 (2007)
64. Frieman MB, "SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism", PLoS Pathog, 6, pp.e1000849~ (2010)
65. Sheahan T, "MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV", PLoS Pathog, 4, pp.e1000240~ (2008)
66. Roberts A, "Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters", J Virol, 79, pp.503~511 (2005)
67. Chu YK, "The SARS-CoV ferret model in an infection-challenge study", Virology, 374, pp.151~163 (2008)
68. Martina BE, "Virology : SARS virus infection of cats and ferrets", Nature, 425, pp.915~ (2003)
69. Rowe T, "Macaque model for severe acute respiratory syndrome", J Virol, 78, pp.11401~11404 (2004)
70. McAuliffe J, "Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys", Virology, 330, pp.8~15 (2004)
71. Lawler JV, "Cynomolgus macaque as an animal model for severe acute respiratory syndrome", PLoS Med, 3, pp.e149~ (2006)
72. Greenough TC, "Pneumonitis and multi-organ system disease in common marmosets(Callithrix jacchus)infected with the severe acute respiratory syndrome-associated coronavirus", Am J Pathol, 167, pp.455~463 (2005)
73. Zhao J, "Rapid generation of a mouse model for Middle East respiratory syndrome", Proc Natl Acad Sci U S A, 111, pp.4970~4975 (2014)
74. Agrawal AS, "Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease", J Virol, 89, pp.3659~3670 (2015)
75. Li K, "Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4", J Infect Dis, 213, pp.712~722 (2016)
76. van Doremalen N, "Animal models of Middle East respiratory syndrome coronavirus infection", Antiviral Res, 122, pp.28~38 (2015)
77. Li K, "Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice", Proc Natl Acad Sci U S A, 114, pp.E3119~ (2017)
78. Cockrell AS, "A mouse model for MERS coronavirus-induced acute respiratory distress syndrome", Nat Microbiol, 2, pp.16226~ (2016)
79. Adney DR, "Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas", Emerg Infect Dis, 22, pp.1031~1037 (2016)
80. Adney DR, "Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels", Emerg Infect Dis, 20, pp.1999~2005 (2014)
81. Munster VJ, "Pneumonia from human coronavirus in a macaque model", N Engl J Med, 368, pp.1560~1562 (2013)
82. Falzarano D, "Infection with MERS-CoV causes lethal pneumonia in the common marmoset", PLoS Pathog, 10, pp.e1004250~ (2014)
83. Yao Y, "An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus", J Infect Dis, 209, pp.236~242 (2014)
84. Linlin Bao, "The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice", Nature, 583(7818), pp.830~833 (2020), Springer Science and Business Media LLC[DOI]
85. Chan JF, "Simulation of the clinical and pathological manifestations of coronavirus disease 2019(COVID-19)in golden Syrian hamster model : implications for disease pathogenesis and transmissibility", Clin Infect Dis (2020)[DOI]
86. Kim YI, "Infection and rapid transmission of SARS-CoV-2 in ferrets", Cell Host Microbe, 27, pp.704~709 (2020)
87. Shi J, "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2", Science, 368, pp.1016~1020 (2020)
88. Rockx B, "Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model", Science, 368, pp.1012~1015 (2020)
89. Yu P, "Age-related rhesus macaque models of COVID-19", Animal Model Exp Med, 3, pp.93~97 (2020)
90. Jing Sun, "Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment", Cell, 182(3), pp.734~743 (2020), Elsevier BV[DOI]
91. Netland J, "Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease", Virology, 399, pp.120~128 (2010)
92. Lamirande EW, "A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters", J Virol, 82, pp.7721~7724 (2008)
93. Menachery VD, "Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-O-methyltransferase activity", J Virol, 88, pp.4251~4264 (2014)
94. Almazán F, "Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate", MBio, 4, pp.e00650~ (2013)
95. Menachery VD, "Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis", MSphere, 2, pp.e00346~ (2017)
96. Takasuka N, "A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice", Int Immunol, 16, pp.1423~1430 (2004)
97. Spruth M, "A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses", Vaccine, 24, pp.652~661 (2006)
98. Kong WP, "Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization", J Virol, 79, pp.13915~13923 (2005)
99. Agrawal AS, "Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus", Hum Vaccin Immunother, 12, pp.2351~2356 (2016)
100. Deng Y, "Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of Middle East respiratory syndrome coronavirus", Emerg Microbes Infect, 7, pp.60~ (2018)
101. Qiang Gao, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369(6499), pp.77~81 (2020), American Association for the Advancement of Science (AAAS)[DOI]
102. He Y, "Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies", J Immunol, 174, pp.4908~4915 (2005)
103. He Y, "Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies : implication for developing subunit vaccine", Biochem Biophys Res Commun, 324, pp.773~781 (2004)
104. Bisht H, "Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein", Virology, 334, pp.160~165 (2005)
105. He Y, "Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein : implication for vaccine design", J Virol, 80, pp.5757~5767 (2006)
106. Kam YW, "Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro", Vaccine, 25, pp.729~740 (2007)
107. Mou H, "The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies", J Virol, 87, pp.9379~9383 (2013)
108. Lan J, "Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge", EBioMedicine, 2, pp.1438~1446 (2015)
109. Zhang N, "Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus", Cell Mol Immunol, 13, pp.180~190 (2016)
110. Tang J, "Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus", Hum Vaccin Immunother, 11, pp.1244~1250 (2015)
111. Du L, "A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses : implication for developing therapeutics and vaccines", PLoS One, 8, pp.e81587~ (2013)
112. Tai W, "A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4(hDPP4)transgenic mice from MERS-CoV infection", Virology, 499, pp.375~382 (2016)
113. Ma C, "Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization : Implication for designing novel mucosal MERS vaccines", Vaccine, 32, pp.2100~2108 (2014)
114. Wang L, "Evaluation of candidate vaccine approaches for MERS-CoV", Nat Commun, 6, pp.7712~ (2015)
115. Jiaming L, "The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus(MERS-CoV)infection", Vaccine, 35, pp.10~18 (2017)
116. Coleman CM, "Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice", Vaccine, 32, pp.3169~3174 (2014)
117. Coleman CM, "MERS-CoV spike nanoparticles protect mice from MERS-CoV infection", Vaccine, 35, pp.1586~1589 (2017)
118. Jung SY, "Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus", Vaccine, 36, pp.3468~3476 (2018)
119. Mortola E, "Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system", FEBS Lett, 576, pp.174~178 (2004)
120. Lu B, "Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice", Immunology, 130, pp.254~261 (2010)
121. Lu X, "Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice", Immunology, 122, pp.496~502 (2007)
122. Liu YV, "Chimeric severe acute respiratory syndrome coronavirus(SARS-CoV)S glycoprotein and influenza matrix 1 efficiently form virus-like particles(VLPs)that protect mice against challenge with SARS-CoV", Vaccine, 29, pp.6606~6613 (2011)
123. Wang C, "MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques", Oncotarget, 8, pp.12686~12694 (2017)
124. Yang ZY, "A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice", Nature, 428, pp.561~564 (2004)
125. Hu H, "Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice", Clin Vaccine Immunol, 14, pp.894~901 (2007)
126. Zakhartchouk AN, "Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines", Vaccine, 23, pp.4385~4391 (2005)
127. Chunling M, "Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB", c mice, 2006, pp.49, 307~318
128. Hu H, "Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice", Biotechnol Lett, 31, pp.1685~1693 (2009)
129. Muthumani K, "A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates", Sci Transl Med, 7, pp.301~ (2015)
130. Al-Amri SS, "Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein", Sci Rep, 7, pp.44875~ (2017)
131. Smith TR, "Immunogenicity of a DNA vaccine candidate for COVID-19", Nat Commun, 11, pp.2601~ (2020)
132. Jingyou Yu, "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", Science, 369(6505), pp.806~811 (2020), American Association for the Advancement of Science (AAAS)[DOI]
133. Czub M, "Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets", Vaccine, 23, pp.2273~2279 (2005)
134. Chen Z, "Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region", J Virol, 79, pp.2678~2688 (2005)
135. Bisht H, "Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice", Proc Natl Acad Sci U S A, 101, pp.6641~6646 (2004)
136. Guo X, "Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus", Immunology, 145, pp.476~484 (2015)
137. Kim E, "Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB", c mice, 2014, pp.32, 5975~5982
138. Dicks MD, "A novel chimpanzee adenovirus vector with low human seroprevalence : improved systems for vector derivation and comparative immunogenicity", PLoS One, 7, pp.e40385~ (2012)
139. Alharbi NK, "ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice", Vaccine, 35, pp.3780~3788 (2017)
140. Munster VJ, "Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model", NPJ Vaccines, 2, pp.28~ (2017)
141. Alharbi NK, "Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels", Sci Rep, 9, pp.16292~ (2019)
142. Volz A, "Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein", J Virol, 89, pp.8651~8656 (2015)
143. Haagmans BL, "An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels", Science, 351, pp.77~81 (2016)
144. Veit S, "CD8+ T cells responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice", Viruses, 10, pp.718~ (2018)
145. Bodmer BS, "Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model", Virology, 521, pp.99~107 (2018)
146. Malczyk AH, "A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform", J Virol, 89, pp.11654~11667 (2015)
147. Wirblich C, "One-health : a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus", J Virol, 91, pp.e02040~ (2017)
148. "Draft landscape of COVID-19 candidate vaccines"[URL]
149. Roberts A, "A mouse-adapted SARS-coronavirus causes disease and mortality in BALB", c mice, 2007, pp.3, e5~
150. Day CW, "A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo", Virology, 395, pp.210~222 (2009)
151. van Doremalen N, "Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4", J Virol, 88, pp.9220~9232 (2014)
152. de Wit E, "The Middle East respiratory syndrome coronavirus(MERS-CoV)does not replicate in Syrian hamsters", PLoS One, 8, pp.e69127~ (2013)
153. Cockrell AS, "Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection", J Virol, 88, pp.5195~5199 (2014)
154. Lauring AS, "Rationalizing the development of live attenuated virus vaccines", Nat Biotechnol, 28, pp.573~579 (2010)
155. See RH, "Comparative evaluation of two severe acute respiratory syndrome(SARS)vaccine candidates in mice challenged with SARS coronavirus", J Gen Virol, 87, pp.641~650 (2006)
156. Stadler K, "SARS vaccine protective in mice", Emerg Infect Dis, 11, pp.1312~1314 (2005)
157. Qin E, "Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine", Vaccine, 24, pp.1028~1034 (2006)
158. Zhou J, "Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys", Vaccine, 23, pp.3202~3209 (2005)
159. Crank MC, "A proof of concept for structure-based vaccine design targeting RSV in humans", Science, 365, pp.505~509 (2019)
160. Valkenburg SA, "Stalking influenza by vaccination with pre-fusion headless HA mini-stem", Sci Rep, 6, pp.22666~ (2016)
161. McLellan JS, "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus", Science, 342, pp.592~598 (2013)
162. Cheng C, "Immunogenicity of a prefusion HIV-1 envelope trimer in complex with a quaternary-structure-specific antibody", J Virol, 90, pp.2740~2755 (2015)
163. Kushnir N, "Virus-like particles as a highly efficient vaccine platform : diversity of targets and production systems and advances in clinical development", Vaccine, 31, pp.58~83 (2012)
164. Tang DC, "Genetic immunization is a simple method for eliciting an immune response", Nature, 356, pp.152~154 (1992)
165. Choi YJ, "A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3", Clin Cancer Res, 26, pp.1616~1623 (2020)
166. Gary EN, "DNA vaccines : prime time is now", Curr Opin Immunol, 65, pp.21~27 (2020)
167. Pardi N, "mRNA vaccines-a new era in vaccinology", Nat Rev Drug Discov, 17, pp.261~279 (2018)
168. "Approval letter - Ervebo (Ebloa Zaire Vaccine, Live)"[URL]
169. Ura T, "Developments in viral vector-based vaccines", Vaccines(Basel), 2, pp.624~641 (2014)
170. Du L, "Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus(SARS-CoV)spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection", J Immunol, 180, pp.948~956 (2008)
171. Choi JH, "Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus", PLoS One, 15, pp.e0232757~ (2020)
172. Widjaja I, "Towards a solution to MERS : protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein", Emerg Microbes Infect, 8, pp.516~530 (2019)
173. Coughlin MM, "Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms", Virology, 394, pp.39~46 (2009)
174. Channappanavar R, "Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection", J Virol, 88, pp.11034~11044 (2014)
175. Zhao J, "T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice", J Virol, 84, pp.9318~9325 (2010)
176. Zhao J, "Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses", Immunity, 44, pp.1379~1391 (2016)
177. Tirado SM, "Antibody-dependent enhancement of virus infection and disease", Viral Immunol, 16, pp.69~86 (2003)
178. Wan Y, "Molecular mechanism for antibody-dependent enhancement of coronavirus entry", J Virol, 94, pp.e02015~ (2020)
179. Polack FP, "A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles", Nat Med, 9, pp.1209~1213 (2003)
180. Polack FP, "A role for immune complexes in enhanced respiratory syncytial virus disease", J Exp Med, 196, pp.859~865 (2002)
181. Kim HW, "Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine", Am J Epidemiol, 89, pp.422~434 (1969)
182. Luo F, "Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine", Virol Sin, 33, pp.201~204 (2018)
183. Houser KV, "Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody", PLoS Pathog, 13, pp.e1006565~ (2017)
184. Verity R, "Estimates of the severity of coronavirus disease 2019 : a model-based analysis", Lancet Infect Dis, 20, pp.669~677 (2020)
185. Cruz-Valdez A, "MF59-adjuvanted influenza vaccine(FLUAD®)elicits higher immune responses than a non-adjuvanted influenza vaccine(Fluzone®) : a randomized, multicenter, Phase III pediatric trial in Mexico", Hum Vaccin Immunother, 14, pp.386~395 (2018)
186. Robertson CA, "Fluzone® high-dose influenza vaccine", Expert Rev Vaccines, 15, pp.1495~1505 (2016)
187. Camilloni B, "Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60 : a literature review", Hum Vaccin Immunother, 11, pp.553~563 (2015)
188. Thomas F. Rogers, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model", Science, 369(6506), pp.956~963 (2020), American Association for the Advancement of Science (AAAS)[DOI]
189. Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci U S A, 117, pp.9490~9496 (2020)
190. Abishek Chandrashekar, "SARS-CoV-2 infection protects against rechallenge in rhesus macaques", Science, 369(6505), pp.812~817 (2020), American Association for the Advancement of Science (AAAS)[DOI]

관련 논문AI추천